PMID- 17088996
OWN - NLM
STAT- MEDLINE
DCOM- 20070222
LR  - 20161124
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 29
IP  - 6
DP  - 2006 Dec
TI  - Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
PG  - 1555-60
AB  - We have previously identified numerous tumor-rejection antigens and their epitope 
      peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes 
      (CTLs) in patients with various types of cancer. In the present study, we 
      attempted to determine which antigens and their peptides are useful in specific 
      immunotherapy for bladder carcinoma (BC) patients, especially those with human 
      leukocyte antigen (HLA)-A24+ alleles. The mRNA expression of a panel of 
      cancer-associated antigens was examined regarding four BC cell lines. As a 
      result, three candidate antigens, including SART3, multidrug 
      resistance-associated protein 3 (MRP3), and polycomb group protein enhancer of 
      zeste homolog 2 (EZH2), were expressed in three of four BC cell lines. 
      Thereafter, antigen-derived peptides which we reported to induce cancer-reactive 
      CTLs from HLA-A24+ patients with various types of cancer were examined for their 
      potential to induce CTLs from peripheral-blood mononuclear cells of HLA-A24+ BC 
      patients. Among these antigen-derived six peptides, SART3109-118, MRP31293-1301, 
      and EZH2735-742 peptides efficiently induced peptide-specific and BC 
      cell-reactive CTLs from HLA-A24+ BC patients. The cytotoxicity against BC cells 
      was dependent on peptide-specific CD8+ T cells. IgG reactive to the SART3109-118 
      peptide was frequently detected in the plasma of BC patients. This information 
      could facilitate the development of effective peptide-based immunotherapy for 
      HLA-A24+ BC patients.
FAU - Komohara, Yoshihiro
AU  - Komohara Y
AD  - Cancer Vaccine Development Division, Kurume University Research Center for 
      Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 
      830-0011, Japan. ycomo@med.kurume-u.ac.jp
FAU - Harada, Mamoru
AU  - Harada M
FAU - Arima, Yoshimi
AU  - Arima Y
FAU - Suekane, Shigetaka
AU  - Suekane S
FAU - Noguchi, Masanori
AU  - Noguchi M
FAU - Yamada, Akira
AU  - Yamada A
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Matsuoka, Kei
AU  - Matsuoka K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (SART3 protein, human)
RN  - 0 (Transcription Factors)
RN  - 1YV0492L5Z (multidrug resistance-associated protein 3)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Polycomb Repressive Complex 2)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/immunology
MH  - Enhancer of Zeste Homolog 2 Protein
MH  - HLA-A Antigens/*immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Immunotherapy, Active/*methods
MH  - Multidrug Resistance-Associated Proteins/immunology
MH  - Polycomb Repressive Complex 2
MH  - RNA, Messenger/biosynthesis/genetics
MH  - RNA-Binding Proteins/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Transcription Factors/immunology
MH  - Urinary Bladder Neoplasms/*immunology/*therapy
EDAT- 2006/11/08 09:00
MHDA- 2007/02/23 09:00
CRDT- 2006/11/08 09:00
PHST- 2006/11/08 09:00 [pubmed]
PHST- 2007/02/23 09:00 [medline]
PHST- 2006/11/08 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2006 Dec;29(6):1555-60.